For: | Chen YX, Yang P, Du SS, Zhuang Y, Huang C, Hu Y, Zhu WC, Yu YY, Liu TS, Zeng ZC. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial. World J Gastroenterol 2023; 29(24): 3871-3882 [PMID: 37426321 DOI: 10.3748/wjg.v29.i24.3871] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i24/3871.htm |
Number | Citing Articles |
1 |
Ajay Patel. Stereotactic Body Radiation Therapy Combined With Immunotherapy for Patients With Hepatocellular Carcinoma‐A Review. Liver International Communications 2024; 5(4) doi: 10.1002/lci2.70005
|
2 |
P.P. Sorochan, N.E. Prokhach, A.M. Nasonova, І.S. Hromakova, S.V. Artiukh, І.А. Hromakova. Immune checkpoint inhibitors and radiotherapy in gastrointestinal cancer treatment. Український радіологічний та онкологічний журнал 2024; 32(2): 244 doi: 10.46879/ukroj.2.2024.244-266
|
3 |
Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha. Treatment of Oligometastatic GI Cancers. American Society of Clinical Oncology Educational Book 2024; 44(1) doi: 10.1200/EDBK_430152
|
4 |
Caressa Hui. Role of Local Therapy for Metastatic Gastrointestinal Malignancies. Digestive Disease Interventions 2024; doi: 10.1055/s-0044-1800822
|
5 |
Seo Hee Choi, Byung min Lee, Jina Kim, Do Young Kim, Jinsil Seong. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study. Journal of Hepatology 2024; 81(1): 84 doi: 10.1016/j.jhep.2024.03.003
|
6 |
Pei Zhang, Chenyan Zhang, Xiaoying Li, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao. Immunotherapy for gastric cancer: Advances and challenges. MedComm – Oncology 2024; 3(4) doi: 10.1002/mog2.92
|
7 |
Hao Su, Yongguang Wei, Xiwen Liao, Guangzhi Zhu, Minhao Peng, Fang Fan, Tao Peng. Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition). Hepatoma Research 2024; doi: 10.20517/2394-5079.2024.70
|
8 |
Zhan Shi, Sihui Zhu, Yuncheng Jin, Liang Qi, Mingzhen Zhou, Ziyan Zhou, Juan Zhang, Baorui Liu, Jie Shen. Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy. Journal of Hepatocellular Carcinoma 2024; : 305 doi: 10.2147/JHC.S452424
|
9 |
Leonardo Stella, Clemence Hollande, Yasmina Ben Merabet, Hugo Fakhouri, Vincent Leclerc, Francesca Romana Ponziani, Mohamed Bouattour. Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results. Expert Opinion on Emerging Drugs 2024; 29(4): 369 doi: 10.1080/14728214.2024.2430493
|
10 |
Rahul Khandekar, Sabi Shrestha, Kawika Dipko, Colleen Conger, Neil B. Newman. Viral-Mediated Hepatocellular Carcinoma: A Review on Mechanisms and Implications for Therapy. Applied Radiation Oncology 2024; 13(3): 15 doi: 10.37549/ARO-D-24-00019
|
11 |
Tong Liu, Guorui Meng, Shihui Ma, Junqi You, Liang Yu, Risheng He, Xudong Zhao, Yunfu Cui. Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1455716
|